{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-271933","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.244012+00:00","generated_at":"2026-06-08T17:43:05.213832+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MAIA reports Q3 net loss $4.9M; THIO shows 100% DCR in second-line NSCLC, FDA IND cleared","bullets":["Cash $6.1M at Sep 30, 2023 vs $10.9M at Dec 31, 2022; net loss $4.9M ($0.36/share) unchanged YoY.","THIO-101 Phase 2 trial achieved 100% disease control rate in second-line NSCLC, exceeding standard of care 53-64%.","FDA cleared THIO IND for U.S. enrollment in THIO-101; 49 patients dosed, enrollment pace exceeding similar trials.","First two subjects on trial reported long-term survival of 14.6 and 12.5 months with no new anti-cancer treatment.","R&D expenses $2.6M (up from $2.3M); G&A $2.4M (up from $1.7M) due to professional fees and investor relations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-271933","json":"https://secwatch.observer/filing/0001193125-23-271933.json","markdown":"https://secwatch.observer/filing/0001193125-23-271933.md","text":"https://secwatch.observer/filing/0001193125-23-271933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000119312523271933/0001193125-23-271933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000119312523271933/d578280d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T17:43:05.213832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c04ad6f47a505bb8faaff5b47b67b86a24e073a","claim":"MAIA Biotechnology, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was approximately $4.9 million, or $0.36 per share, for the quarter ended September 30, 2023, EPS $0.36 per share.","evidence_excerpt":"MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1878313/000119312523271933/0001193125-23-271933-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was approximately $4.9 million, or $0.36 per share, for the quarter ended September 30, 2023"},{"label":"EPS","value":"$0.36 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}